Reason for request
Re-assessment of methylphenidate-based proprietary products in attention-deficit hyperactivity disorder in response to a request from the Directorate-General for Health.
Clinical Benefit
| Substantial |
The actual benefit of CONCERTA LP proprietary products is substantial in the context of the overall therapeutic management of ADHD in children aged 6 years and over when psychological, educational and social management alone prove insufficient. |
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
N9XUsMp8EJwHSrC6
